EA201290339A1 - Комбинация - Google Patents
КомбинацияInfo
- Publication number
- EA201290339A1 EA201290339A1 EA201290339A EA201290339A EA201290339A1 EA 201290339 A1 EA201290339 A1 EA 201290339A1 EA 201290339 A EA201290339 A EA 201290339A EA 201290339 A EA201290339 A EA 201290339A EA 201290339 A1 EA201290339 A1 EA 201290339A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mek
- mtor
- inhibitor
- combination
- iodophenylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Новая комбинация, содержащая ингибитор MEK N-{3-[3-циклопропил-5-(2-фтор-4-йодфениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]фенил}ацетамид или его фармацевтически приемлемую(ый) соль или сольват, с ингибитором mTOR, фармацевтические композиции, содержащие то же самое, и способы применения таких комбинаций и композиций в лечении состояний, в которых ингибирование MEK и/или mTOR является благотворным, например ракового заболевания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26181309P | 2009-11-17 | 2009-11-17 | |
PCT/US2010/056931 WO2011062930A1 (en) | 2009-11-17 | 2010-11-17 | Combination |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201290339A1 true EA201290339A1 (ru) | 2012-12-28 |
EA022637B1 EA022637B1 (ru) | 2016-02-29 |
Family
ID=44059949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201290339A EA022637B1 (ru) | 2009-11-17 | 2010-11-17 | Комбинация |
Country Status (17)
Country | Link |
---|---|
US (4) | US20120283279A1 (ru) |
EP (1) | EP2501379B1 (ru) |
JP (1) | JP5834370B2 (ru) |
KR (1) | KR20120117779A (ru) |
CN (2) | CN104382906A (ru) |
AU (1) | AU2010322105B2 (ru) |
BR (1) | BR112012011677A8 (ru) |
CA (1) | CA2781063A1 (ru) |
EA (1) | EA022637B1 (ru) |
ES (1) | ES2578191T3 (ru) |
IL (1) | IL219786A (ru) |
MX (1) | MX2012005758A (ru) |
PL (1) | PL2501379T3 (ru) |
PT (1) | PT2501379E (ru) |
SG (1) | SG10201407558TA (ru) |
WO (1) | WO2011062930A1 (ru) |
ZA (1) | ZA201203444B (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2640390A4 (en) * | 2010-11-17 | 2014-08-06 | Glaxosmithkline Ip No 2 Ltd | METHODS OF TREATING CANCER |
TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
WO2013070976A1 (en) * | 2011-11-08 | 2013-05-16 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
RU2015117483A (ru) * | 2012-10-12 | 2016-12-10 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинации |
CA2946759A1 (en) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003248813A1 (en) * | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
MXPA06014478A (es) * | 2004-06-11 | 2007-03-21 | Japan Tobacco Inc | Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer. |
KR20100089082A (ko) * | 2007-10-15 | 2010-08-11 | 아스트라제네카 아베 | 조합 059 |
-
2010
- 2010-11-17 AU AU2010322105A patent/AU2010322105B2/en not_active Ceased
- 2010-11-17 CN CN201410535441.1A patent/CN104382906A/zh active Pending
- 2010-11-17 BR BR112012011677A patent/BR112012011677A8/pt not_active IP Right Cessation
- 2010-11-17 PT PT108320680T patent/PT2501379E/pt unknown
- 2010-11-17 EA EA201290339A patent/EA022637B1/ru not_active IP Right Cessation
- 2010-11-17 JP JP2012539983A patent/JP5834370B2/ja not_active Expired - Fee Related
- 2010-11-17 KR KR1020127015509A patent/KR20120117779A/ko active IP Right Grant
- 2010-11-17 MX MX2012005758A patent/MX2012005758A/es active IP Right Grant
- 2010-11-17 PL PL10832068.0T patent/PL2501379T3/pl unknown
- 2010-11-17 WO PCT/US2010/056931 patent/WO2011062930A1/en active Application Filing
- 2010-11-17 SG SG10201407558TA patent/SG10201407558TA/en unknown
- 2010-11-17 US US13/509,955 patent/US20120283279A1/en not_active Abandoned
- 2010-11-17 CN CN2010800616827A patent/CN102724979A/zh active Pending
- 2010-11-17 ES ES10832068.0T patent/ES2578191T3/es active Active
- 2010-11-17 CA CA2781063A patent/CA2781063A1/en not_active Abandoned
- 2010-11-17 EP EP10832068.0A patent/EP2501379B1/en active Active
-
2012
- 2012-05-11 ZA ZA2012/03444A patent/ZA201203444B/en unknown
- 2012-05-14 IL IL219786A patent/IL219786A/en not_active IP Right Cessation
-
2014
- 2014-06-19 US US14/309,262 patent/US20140303195A1/en not_active Abandoned
-
2015
- 2015-09-24 US US14/863,709 patent/US20160008368A1/en not_active Abandoned
-
2016
- 2016-11-16 US US15/352,813 patent/US20170065593A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2501379A4 (en) | 2013-07-31 |
PT2501379E (pt) | 2016-06-09 |
US20120283279A1 (en) | 2012-11-08 |
CA2781063A1 (en) | 2011-05-26 |
ZA201203444B (en) | 2013-01-31 |
CN102724979A (zh) | 2012-10-10 |
AU2010322105A1 (en) | 2012-05-31 |
ES2578191T3 (es) | 2016-07-21 |
US20160008368A1 (en) | 2016-01-14 |
EP2501379A1 (en) | 2012-09-26 |
AU2010322105B2 (en) | 2014-05-08 |
JP5834370B2 (ja) | 2015-12-16 |
SG10201407558TA (en) | 2015-01-29 |
JP2013511525A (ja) | 2013-04-04 |
WO2011062930A1 (en) | 2011-05-26 |
EP2501379B1 (en) | 2016-03-23 |
EA022637B1 (ru) | 2016-02-29 |
BR112012011677A2 (pt) | 2018-03-20 |
BR112012011677A8 (pt) | 2018-06-12 |
US20140303195A1 (en) | 2014-10-09 |
PL2501379T3 (pl) | 2016-10-31 |
CN104382906A (zh) | 2015-03-04 |
IL219786A0 (en) | 2012-07-31 |
IL219786A (en) | 2016-05-31 |
MX2012005758A (es) | 2012-06-19 |
KR20120117779A (ko) | 2012-10-24 |
US20170065593A1 (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500776A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
PH12020500028A1 (en) | Crystalline forms of a bruton`s tyrosine kinase inhibitor | |
EA201390913A1 (ru) | Новая фармацевтическая композиция | |
WO2012068096A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
WO2012068106A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
CO6531498A2 (es) | COMBINACIÓN QUE COMPRENDE UN INHIBIDORDE MEK Y UN INHIBIDOR DE B- RAF úTIL EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS | |
AR086656A1 (es) | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a | |
EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
MX2010010300A (es) | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. | |
WO2012071509A3 (en) | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture | |
CL2011001361A1 (es) | Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios. | |
EA201290339A1 (ru) | Комбинация | |
CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
MY150747A (en) | Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
CL2009001019A1 (es) | Compuestos derivados de pirrolo[1,2-c]imidazol-3-ona, imidazo[indol-3-ona e imidazo[1,5-a]piridin-3-ona sustituidos; procedeimiento de preparacion; su composicion farmaceutica; utiles en el tratamiento de la diabetes, obesidad, trastornos de ingesta d comida o dislepidemia. | |
EA201492104A1 (ru) | Ингибитор jak1/2 | |
EP2549874A4 (en) | SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | |
EA201791411A1 (ru) | Новая фармацевтическая композиция | |
EA201270445A1 (ru) | Комбинация | |
EA201390757A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА | |
EA201500882A1 (ru) | Комбинация |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Registration of transfer of a eurasian patent by assignment | ||
PC4A | Registration of transfer of a eurasian patent by assignment | ||
PC4A | Registration of transfer of a eurasian patent by assignment | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |